Search Results - "Schutt, P"

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma by Schütt, P., Ebeling, P., Buttkereit, U., Brandhorst, D., Opalka, B., Hoiczyk, M., Flasshove, M., Hense, J., Bojko, P., Metz, K., Moritz, T., Seeber, S., Nowrousian, M. R.

“…:  The present study aimed to evaluate the side‐effects and efficacy of thalidomide in combination with an anthracycline‐containing chemotherapy regimen in…”
Get full text

Redeeming Law: Christian Calling and the Legal Profession by Schutt, Michael P

“…Michael Schutt provides insight and guidance about being both a Christian and a lawyer. Some may be skeptical, but he discusses the ins and outs of both law…”
Get full text

Production and separation of positron emitters for hadron therapy at FRS-Cave M by Haettner, E., Geissel, H., Franczak, B., Kostyleva, D., Purushothaman, S., Tanaka, Y.K., Amjad, F., Boscolo, D., Dickel, T., Graeff, C., Hessler, C., Hornung, C., Kazantseva, E., Kuzminchuk, N., Morrissey, D., Mukha, I., Pietri, S., Rocco, E., Roy, P., Roesch, H., Schuy, C., Schütt, P., Weber, U., Weick, H., Zhao, J., Durante, M., Parodi, K., Scheidenberger, C.

“…The FRagment Separator FRS at GSI is a versatile spectrometer and separator for experiments with relativistic in-flight separated short-lived exotic beams. One…”
Get full text

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival by Schütt, Philipp, Ebeling, Peter, Buttkereit, Ulrike, Brandhorst, Dieter, Opalka, Bertram, Poser, Miriam, Müller, Siemke, Flasshove, Michael, Moritz, Thomas, Seeber, Siegfried, Nowrousian, Mohammad Resa

“…The aim of this study was to assess the side effects and the efficacy of thalidomide alone or in combination with dexamethasone in relapsed multiple myeloma…”
Get full text

FDG-PET/CT in re-staging of patients with lymphoma by Freudenberg, L S, Antoch, G, Schütt, P, Beyer, T, Jentzen, W, Müller, S P, Görges, R, Nowrousian, M R, Bockisch, A, Debatin, J F

“…The aim of this study was to evaluate the clinical significance of combined fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography…”
Get full text

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment by SCHÜTT, Philipp, BUTTKEREIT, Ulrike, BRANDHORST, Dieter, LINDEMANN, Monika, SCHMIEDL, Sven, GROSSE-WILDE, Hans, SEEBER, Siegfried, MOHAMMAD RESA NOWROUSIAN, OPALKA, Bertram, MORITZ, Thomas

“…While vaccination with antigen-pulsed dendritic cells (DCs) represents a promising therapeutic strategy in multiple myeloma (MM), clinical benefit, so far, has…”
Get full text

Experiment on space charge driven nonlinear resonance crossing in an ion synchrotron by Franchetti, G., Chorniy, O., Hofmann, I., Bayer, W., Becker, F., Forck, P., Giacomini, T., Kirk, M., Mohite, T., Omet, C., Parfenova, A., Schütt, P.

“…Trapping of particles in nonlinear resonances in the presence of space charge and synchrotron motion may be a source of beam halo generation and beam loss in…”
Get full text

Occurrence of corneal microcystoid alterations under administration of belantamab mafodotin for multiple myeloma by Zimmermann, Julian, Esser, E, Eter, N, Schütt, P, Uhlig, C E

Get more information

Design of HVDC converter stations with respect to audible noise requirements by Smede, H., Johansson, C.-G., Winroth, O., Schutt, H.-P.

“…The purpose of this paper is to provide an overview of the engineering methods, tools, design solutions and verification methods used in the design of HVDC…”
Get full text

Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution by Müller, S, Schütt, P, Bojko, P, Nowrousian, M R, Hense, J, Seeber, S, Moritz, T

“…Hemolytic uremic syndrome (HUS) has been described following the administration of multiple antineoplastic agents, most notably mitomycin C. More recently,…”
Get full text

Imaging of brain metastases of bronchial carcinomas with 7 T MRI - initial results by Mönninghoff, C, Maderwald, S, Theysohn, J M, Schütt, P, Gauler, T, Kraff, O, Ladd, M E, Ladd, S C, Wanke, I

“…To compare the depiction of brain metastases of bronchial carcinomas on susceptibility-weighted and contrast-enhanced images with 7 T and at 1.5 T MRI. Twelve…”
Get more information

Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients by Glasmacher, A., Cornely, O. A., Orlopp, K., Reuter, S., Blaschke, S., Eichel, M., Silling, G., Simons, B., Egerer, G., Siemann, M., Florek, M., Schnitzler, R., Ebeling, P., Ritter, J., Reinel, H., Schütt, P., Fischer, H., Hahn, C., Just-Nuebling, G.

“…Background: Caspofungin has shown efficacy in empirical antifungal therapy in neutropenic patients, refractory invasive Aspergillus infections and invasive…”
Get full text

Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas by Schütt, P., Passon, J., Ebeling, P., Welt, A., Müller, S., Metz, K., Moritz, T., Seeber, S., Nowrousian, M. R.

“…High‐dose chemotherapy (HD‐CT) with autologous stem cell transplantation is considered to be the treatment of choice for relapsed high‐grade non‐Hodgkin's…”
Get full text

Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients by Rebmann, Vera, Schütt, Philipp, Brandhorst, Dieter, Opalka, Bertram, Moritz, Thomas, Reza Nowrousian, Mohammad, Grosse-Wilde, Hans

“…Abstract Major histocompatibility complex class I-related chain A (MICA) molecules are frequently expressed in lymphoproliferative malignancies including…”
Get full text

Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin's lymphoma by Schütt, P, Zimmermann, K, Derks, C, Ebeling, P, Welt, A, Poser, M, Hense, J, Metz, K, Anhuf, J, Sandmann, M, Neise, M, Moritz, T, Stuschke, M, Niederle, N, Seeber, S, Nowrousian, Mohammad R

“…Introduction Anthracyline-based chemotherapy is the treatment of choice for patients with aggressive B-cell non-Hodgkin's lymphoma (NHL). However,…”
Get full text

1301P Sequential therapy of metastatic pancreatic ductal adenocarcinoma (PDAC) after failure of gemcitabine plus nab-paclitaxel with either 5-FU/folinic acid (5FU/LV) plus irinotecan (FOLFIRI) followed by 5FU/LV plus oxaliplatin (OFF) or the reverse sequence: The PANTHEON trial (AIO PAK 0116) by Modest, D.P., Heinemann, V., Schütt, P., Angermeier, S., Haberkorn, M., Waidmann, O., Graeven, U., Wille, K., Kunzmann, V., Henze, L., Constantin, C., De Wit, M., Denzlinger, C., Kurreck, A., Alig, A.H.S., Stahler, A., Pelzer, U., Stintzing, S., Oettle, H.

Get full text

53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116) by Vogel, A., Wenzel, P., Folprecht, G., Schütt, P., Wege, H., Kretzschmar, A., Jacobasch, L., Ziegenhagen, N., Boeck, S., Kanzler, S., Mohm, J., Belle, S., Pink, D., Götze, T.O., Goekkurt, E., Graeven, U., Schaaf, M., Kirstein, M., Saborowski, A.

Get full text

679P Final results on efficacy and patient reported outcomes (PRO) of a randomized phase II trial investigating nivolumab switch-maintenance after TKI induction in metastatic clear cell renal cell carcinoma (mRCC) patients (NIVOSWITCH) by Darr, C., Zschäbitz, S., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Müller, L., Metz, M., Bergmann, L., Steiner, T., Lorch, A., Schütt, P., Rafiyan, M-R., Hellmis, E., Hinke, A., Mänz, M., Meiler, J., Kretz, T., Flörcken, A., Grünwald, V.

Get full text

The clinical significance of soluble human leukocyte antitgen class-I, ICTP, and RANKL molecules in multiple myeloma patients by Schütt, Philipp, Rebmann, Vera, Brandhorst, Dieter, Wiefelspütz, Johannes, Ebeling, Peter, Opalka, Bertram, Seeber, Siegfried, Nowrousian, Mohammad R, Moritz, Thomas, Grosse-Wilde, Hans

“…Summary Because of the variable clinical course of multiple myeloma, the identification of prognostic parameters is of clinical interest. Therefore, we…”
Get full text

959P - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH) by Grünwald, V., Grüllich, C., Ivanyi, P., Wirth, M., Staib, P., Schostak, M., Dargatz, P., Müller, L., Metz, M., Bergmann, L., Welslau, M.K., Schütt, P., Rafiyan, M.-R., Hellmis, E., Hinke, A., Meiler, J., Kretz, T., Loidl, W.C., Flörcken, A., Steiner, T.

“…Tyrosine kinase inhibitors (TKI) and nivolumab (NIVO) are key components of systemic therapies in metastatic renal cell carcinoma (mRCC). We tested if TKI…”
Get full text